Quoting Sara Tolaney, Chief of Division of Breast Oncology at Dana Farber Cancer Institute, on X/Twitter:
”TROPICS-02 Overall Survival data now published in The Lancet!
Sacituzumab govitecan improved PFS, ORR, OS, & QOL c/w TPC in pts with pretreated metastatic HR+ BC. Benefit seen across all Trop-2 exp levels.”
For the article click here.
Source: Sara Tolaney/Twitter